2025-12-17 - Analysis Report
Here's a comprehensive analysis of TransMedics Group Inc. (TMDX), combining the provided data points and news headlines.

**1) Return Rate Comparison & Alpha/Beta Analysis:**

*   **Company Overview:** Transmedics Group Inc. is a medical technology company pioneering a novel approach to organ preservation for transplantation.
*   **Performance vs. S&P 500 (VOO):**
    *   TMDX Cumulative Return: 207.75%
    *   VOO Cumulative Return: 75.05%
    *   Divergence: 145.3 (Relative Divergence: 68.3) - TMDX has significantly outperformed the S&P 500, with a substantial divergence in cumulative returns. The relative divergence suggests that the current divergence is positioned near the upper two-thirds of its historical range relative to the S&P 500.
*   **Alpha/Beta Analysis:**

    | Year       | CAGR    | MDD   | Alpha   | Beta | Cap(B) |
    |------------|---------|-------|---------|------|--------|
    | 2019-2021  | -18.0%  | 83.5% | -61.0%  | -0.0 | 0.7    |
    | 2020-2022  | 94.0%   | 83.5% | 95.0%   | 0.0  | 2.1    |
    | 2021-2023  | 65.0%   | 80.5% | 64.0%   | 0.1  | 2.7    |
    | 2022-2024  | 130.0%  | 85.5% | 109.0%  | 0.1  | 2.1    |
    | 2023-2025  | 128.0%  | 85.5% | 64.0%   | 0.3  | 4.3    |

    *   **CAGR (Compound Annual Growth Rate):**  Volatile, with negative returns in the 2019-2021 period, followed by strong growth in subsequent periods.
    *   **MDD (Maximum Drawdown):**  High drawdown across all periods (above 80%), indicating significant volatility and risk.
    *   **Alpha:**  Generally positive, showing outperformance relative to the market (risk-adjusted). The highest Alpha was observed in the 2020-2022 and 2022-2024 periods.
    *   **Beta:** Low Beta values suggest that TMDX is not highly correlated with the overall market. It's generally not heavily influenced by broader market movements.
    *   **Cap(B):**  Shows the market capitalization of the company in Billions of Dollars.
*   **Analysis:** TMDX has delivered substantial outperformance, as reflected in its cumulative return. However, the high MDD figures and fluctuating CAGR highlight the stock's volatility and risk. The positive Alpha values confirm that TMDX has generated returns above what would be expected based on its risk (Beta).

**2) Recent Stock Price Fluctuations:**

*   Current Price: 125.04
*   Previous Close: 123.15
*   Change: +1.53
*   5-day SMA: 126.76
*   20-day SMA: 134.43
*   60-day SMA: 124.50
*   **Analysis:** The current price is below the 5-day and 20-day SMAs but above the 60-day SMA.  The 5-day SMA is below the 20-day SMA, which could signal a potential short-term downward trend. The recent increase in price (change of 1.53 from previous close) could be a short-term rebound.

**3) Technical Indicators:**

*   MRI: 0.7 (Medium Investment Recommended)
*   RSI: 9.75 (Oversold)
*   PPO: -1.69 (Negative trend)
*   Hybrid Signal: cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 1.2% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   Recent (20 days) relative divergence change: -7.1 (short-term decline)
*   Expected Return: 43.9% (long-term)
*   **Analysis:**
    *   The RSI is extremely low, indicating that the stock is oversold and could experience a bounce. However, oversold conditions can persist for extended periods.
    *   The PPO being negative supports the conclusion that the stock is in a downtrend.
    *   The Hybrid Signal suggests a "Buy" recommendation, seeing a large opportunity.
    *   The Market Risk Indicator (MRI) is medium, which aligns with other indicators that the stock is medium risky.
    *   The significant drop in recent divergence and long term expectation shows short term pain but long term gain.

**4) Recent News & Significant Events:**

*   **Negative:**
    *   **[2025-12-13]** Braidwell LP Cuts Stock Holdings in TransMedics Group, Inc.: This indicates institutional investors are reducing their positions, which can create selling pressure.
    *   **[2025-12-06]** TransMedics Stock Drop Looks Sharp, But How Deep Can It Go?:  This highlights concerns about the sustainability of the stock's price.
    *   **[2025-12-08]** TransMedics Group Stock (TMDX) Opinions on Recent Insider Sales:  Insider selling can be viewed negatively by investors.
*   **Positive:**
    *   **[2025-12-01]** 3 Top Stocks to Buy in December:  Positive media coverage can attract investors.
    *   **[2025-10-31]** Here's Why TransMedics (TMDX) is a Strong Growth Stock:  This reinforces the long-term growth potential of the company.
    *   **[2025-09-24]** Here's Why TransMedics (TMDX) is a Strong Growth Stock: Positive long-term outlook.
*   **Analysis:** Recent news paints a mixed picture. Some news items highlight positive long-term growth prospects, while others express concerns about short-term price declines and institutional selling.

**4-2) Analyst Opinions:**

*   Consensus: Buy
*   Mean Rating: 1.67 (~Buy)
*   Number of Opinions: 11
*   Target Price (avg/high/low): 144.64 / 170.00 / 114.00
*   Recent Rating Changes: No recent changes indicated.
*   **Analysis:**  The analyst consensus is generally positive, with a "Buy" rating and an average target price significantly above the current price. This suggests that analysts, on average, believe the stock is undervalued.

**5) Comprehensive Analysis:**

TransMedics (TMDX) presents a complex picture.  The company has demonstrated substantial outperformance compared to the S&P 500, driven by its innovative technology and potential for growth in the organ transplantation field. Analyst ratings and expected return numbers signal opportunity.

However, investors should carefully consider the following factors:

*   **Volatility:** High MDD and fluctuating CAGR highlight the stock's significant volatility.
*   **Recent Price Action:** The stock is currently below its 5-day and 20-day SMAs, indicating a possible short-term downtrend, although the very oversold RSI could trigger a rebound.
*   **Recent News:** Recent institutional selling and concerns about price drops raise some caution, even though there are positive long-term growth stories.
*   **Risk Tolerance:** The MRI suggests medium risk, but individual investors should assess their own comfort level with volatility.

**In conclusion:** TMDX offers the potential for high returns, but it comes with significant risk. Investors should conduct thorough due diligence and carefully consider their risk tolerance before investing. Given the recent price weakness and negative news, a cautious approach may be warranted in the short term. However, the positive analyst ratings and potential long term return suggests a good opportunity if investors are aware of the associated risk.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.